19-22 June 2013 Lugano
161-P | BURKITTS LYMPHOMAS THAT ARISE SPONTANEOUSLY IN VKMYC MICE SHARE SIMILAR MUTATIONS WITH THE HUMAN DISEASE AND ARE ACCELERATED BY DIVERSE SURVIVAL SIGNALS. | marta chesi | Received |
162-P | PRO-ONCOGENIC FUNCTIONS OF HSP105 IN HUMAN B-CELL NON-HODGKIN LYMPHOMAS | Massimo Di Nicola | Received |
163-P | DIMERIZATION AND MONOUBIQUITINATION OF THE PARACASPASE MALT1 ARE REQUIRED FOR THE SURVIVAL OF CELLS DERIVED FROM ABC DLBCL | Margot Thome-Miazza | Received |
166-P | EBV-SPECIFIC MICRO-RNA VIA EXOSOME: A KEY INTER-CELLULAR MACHINERY BETWEEN EBV TUMOR AND TUMOR-SURROUNDING IMMUNE CELLS? | Kotani Ai | Received |
167-P | RICHTER SYNDROME (RS) PROMOTER METHYLATION DIFFERS FROM DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) | Afua Adjeiwaa Mensah | Received |
168-P | THE GENOMIC LANDSCAPE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) | Esteban Braggio | Received |
169-P | QUANTITATIVE ULTRA DEEP SEQUENCING TO CHARACTERIZE CLONAL EVOLUTION OF FOLLICULAR LYMPHOMA | Richard Burack | Received |
172-P | SELECTIVE QUANTIFICATION OF BMI-1 LEVELS IN THE NUCLEI OF FOLLICULAR LYMPHOMA CELLS SHOWS ITS ASSOCIATIONS WITH EZH2 GENE MUTATION AND REDUCED OVERALL SURVIVAL, INDEPENDENT OF FLIPI | Naif AlJohani | Received |
173-P | MUM-1 IS A STRONG PROGNOSTIC IMMUNOHISTOCHEMICAL MARKER IN FOLLICULAR LYMPHOMA: COMPUTERIZED IMAGE ANALYSIS OF THE FL-2000 AND PRIMA RANDOMIZED GELA TRIALS. | Luc Xerri | Received |
174-P | STRONG CD180 EXPRESSION : A NEW MARKER OF MARGINAL B-CELL LYMPHOMAS | Lucile BASEGGIO | Received |
175-P | Multidimensional flow cytometry for sensitive evaluation of patients with IgM MGUS or Waldenstrms Macroglobulinemia and differential diagnosis with other lymphomas | Bruno Paiva | Received |
176-P | CD70 T CELLS ARE INDICATIVE OF TGF--MEDIATED IMMUNE SUPPRESSION AND PREDICT A POOR OUTCOME IN FOLLICULAR LYMPHOMA PATIENTS | Zhizhang Yang | Received |
178-P | OVEREXPRESSION OF MYC, BCL2, MYC/BCL2, IGM, AS WELL AS NON-GERMINAL CENTRE B-CELL LIKE IMMUNOPHENOTYPE PREDICT A WORSE PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN A SERIES OF 670 DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS: A LYSA STUDY. | Molina Thierry | Received |
180-P | PROGNOSTIC SIGNIFICANCE AND PHENOTYPIC MANIFESTATIONS OF MYC/BCL2 PROTEIN CO-EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH EXTRANODAL ORGAN INVOLVEMENT: A REPORT OF THE INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY | Anusha Madadi | Received |
181-P | MICRORNAS OF THE MIR-17-92 CLUSTER PREDICT FOR OUTCOME IN R-CHOP-TREATED DIFFUSE LARGE B-CELL LYMPHOMA AND ARE SIGNIFICANTLY ASSOCIATED WITH EXPRESSION OF MYC PROTEIN | Rachel Culpin | Received |
182-P | GENETIC ABNORMALITIES IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA (B-UCL): THE NEBRASKA EXPERIENCE | ANAMARIJA PERRY | Received |
186-P | PROGNOSTIC ROLE OF HISTOLOGICAL GRADE 3A IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. RESULTS OF AN F2-STUDY DATABASE | Monica Bellei | Received |
188-P | VIROLOGIC RESPONSE IMPROVES PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS. | Jean Marie Michot | Received |
189-P | INFLUENCE OF LIFESTYLE FACTORS ON THE EXPRESSION OF TUMOR-RELATED MICROENVIRONMENT T-CELLS AND THE IMPACT ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) | Andrew Evens | Received |
190-P | Comparison of CHOP v. CVP treatment in 837 United States Veterans with untreated follicular lymphoma | Kenneth R. Carson | Received |
191-P | A MULTICENTER PHASE II TRIAL OF BORTEZOMIB (B) COMBINED WITH RITUXIMAB (R) THERAPY FOR UNTREATED HIGH TUMOR BURDEN (HTB) INDOLENT NON-HODGKIN LYMPHOMA (NHL) | Andrew Evens | Received |
192-P | FLUDARABINE-MITOXANTRONE-RITUXIMAB REGIMEN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR NON-HODGKIN | Pier Luigi Zinzani | Received |
194-P | PHARMACOKINETICS (PK), SAFETY, AND OVERALL RESPONSE RATE (ORR) ACHIEVED WITH SUBCUTANEOUS (SC) RITUXIMAB (R) PLUS CHEMOTHERAPY (CT) WERE COMPARABLE TO THOSE WITH INTRAVENOUS (IV) ADMINISTRATION IN THE 1LTREATMENT OF PATIENTS (PTS) WITH FL | Chelsy Viereck | Received |
196-P | FCGR3A AND FCGR2A POLYMORPHISMS DO NOT PREDICT RESPONSE RATE OR DURATION IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH SINGLE-AGENT RITUXIMAB: A PROSPECTIVE CORRELATIVE ANALYSIS FROM THE RESORT STUDY (ECOG E4402). | Brad Kahl | Received |
199-P | THE USE OF RITUXIMAB AT FIRST-LINE DOES NOT IMPAIR THE EFFICACY OF SECOND-LINE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA. RESULTS OF THE REFOLL STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL). | Giuseppe Rossi | Received |
201-P | TREATMENT OF FOLLICULAR LYMPHOMA WITH RADIOIMMUNOTHERAPY DATA FROM THE RADIOIMMUNOTHERAPY NETWORK, AN INTERNATIONAL DATA BASE ON DAILY CLINICAL PRACTICE | Christian Scholz | Received |
203-P | A POINT SCORE SIMPLIFICATION FOR PRACTICAL USE OF THE RISK STRATIFICATION FOR SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) BASED ON HEMOGLOBIN, PLATELET COUNT, HIGH LDH LEVEL AND EXTRAHILAR LYMPHADENOPATHY. | Carlos Montalban | Received |
204-P | PERFORMANCE OF THE MONOCLONAL ASSAY FOR CIRCULATING FREE LIGHT CHAINS (FLC) IN AL AMYLOIDOSIS | Giovanni Palladini | Received |
205-P | B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AMONG ISRAELIS AND PALESTINIANS: DIVERSE DISEASE PATTERNS AND RISK FACTORS IN POPULATIONS IN GEOGRAPHIC PROXIMITY | Ora Paltiel | Received |
206-P | EFFECT OF PLACE OF RESIDENCE AND CARE ON SURVIVAL OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA | Diego Villa | Received |
207-P | AN ENHANCED INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) FOR RISK STRATIFICATION OF DLBCL PATIENTS IN THE RITUXIMAB ERA: VALIDATION USING THE BRITISH COLUMBIA CANCER AGENCY (BCCA) DATABASE | Zheng Zhou | Received |
208-P | IMPACT OF GENDER, BODY MASS INDEX (BMI) AND BODY SURFACE AREA (BSA) ON OUTCOMES OF DLBCL PATIENTS TREATED WITH RITUXIMAB (R): ANALYSIS OF THE U.S. NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) DATABASE | Zheng Zhou | Received |
212-P | R-CHOEP-14 IMPROVES OVERALL SURVIVAL IN YOUNG HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH R-CHOP-14. AN UPDATED ANALYSIS WITH 5 YEARS MEDIAN FOLLOW UP OF THE POPULATION-BASED INVESTIGATION FROM THE DANISH LYMPHOMA GROUP. | Anne Ortved Gang | Received |
214-P | PHASE 2 STUDY OF RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE WITH BORTEZOMIB (VCR-CAP) OR VINCRISTINE (R-CHOP) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL-LIKE (GCB) DLBCL | Fritz Offner | Received |
215-P | RESULTS OF A PHASE 2 MULTICENTER STUDY OF THE ADDITION OF RITUXIMAB (R) TO CODOX-M/IVAC FOR UNTREATED BURKITTS LYMPHOMA (BL): IMPACT OF PLASMA AND CEREBROSPINAL FLUID (CSF) R LEVELS | Andrew Evens | Received |
216-P | TUMOR EPSTEIN-BARR VIRUS (EBV) REPLICATION IS ASSOCIATED WITH EARLY-ONSET AND AGGRESSIVE BEHAVIOR OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) | Jordina Rovira Solé | Received |
217-P | EPSTEIN BARR VIRUS (EBV) PRIMO-INFECTIONS (PI) AND REACTIVATION (REA) TREATMENT AFTER HEART TRANSPLANTATION, IN PREVENTION OF POST-TRANSPLANTATION LYMPHOPROLIFERATION DISEASE (PTLD). | Sylvain Choquet | Received |
218-P | RISK-TAILORED CNS PROPHYLAXIS IN A MONOINSTITUTIONAL SERIES OF 194 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED IN THE RITUXIMAB ERA | Andrés Ferreri | Received |
220-P | INFLUENCE OF PRIOR RITUXIMAB ON THE RESULTS OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A GELTAMO STUDY. | ALBA MARÍA REDONDO | Received |
221-P | COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IS AN ESSENTIAL TOOL TO SUPPORT TREATMENT DECISIONS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). RESULTS OF A MULTICENTER STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL) | Alessandra Tucci | Received |
222-P | ELDERLY IPI (EIPI) IN DLBCL PTS AGE 60 Y TREATED WITH RCHOP: INTERNATIONAL VALIDATION STUDY USING DATA FROM RICOVER-60 (GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP) AND LNH 98-5 (GROUPE DETUDE DE LYMPHOME DADULTES) | Ranjana Advani | Received |
224-P | TREATMENT APPROACH AND CAUSE SPECIFIC SURVIVAL IN ELDERLY PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA. | Anna Dyszkiewicz-Korpanty | Received |
225-P | PATIENT-REPORTED SYMPTOMS ARE STILL THE SINGLE MOST IMPORTANT FACTOR FOR DETECTING LYMPHOMA RELAPSE | Tarec Christoffer El-Galaly | Received |
227-P | IMMUNOGENETIC ANALYSIS OF THE B-CELL REPERTOIRE OF INDOLENT MCL WITH A SPLENIC PRESENTATION | clémentine sarkozy | Received |
230-P | PREEMPTIVE IMMUNOTHERAPY WITH RITUXIMAB SIGNIFICANTLY PROLONGS THE DISEASE-FREE SURVIVAL IN PATIENTS WITH MOLECULAR RELAPSE OF MANTLE CELL LYMPHOMA | David Salek | Received |
235-P | LONG-TERM FOLLOW-UP OF THE PHASE II STUDY OF SMILE CHEMOTHERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: THE NK-CELL TUMOR STUDY GROUP (NKTSG) STUDY | Ritsuro Suzuki | Received |
239-P | MANAGEMENT AND PROGNOSIS OF PATHOLOGICAL FRACTURES (PF) IN A SERIES OF 373 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF THE BONE (THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG 14 STUDY) | Silvia Govi | Received |
241-P | HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT) | Eisei Kondo | Received |
242-P | INTENSIVE THERAPY OF THE PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA | Elena Baryakh | Received |
243-P | CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA IN GASTROINTESTINAL TRACT: RESULTS OF MULTICENTER RETROSPECTIVE ANALYSIS | Won Seog Kim | Received |
244-P | Non-coding RNAs in cerebrospinal fluid as biomarker for primary central nervous system lymphoma | Alexander Baraniskin | Received |
246-P | SIMILAR CHEMOKINE RECEPTOR PROFILES IN PCNSL AND SECONDARY CNS INVOLVEMENT OF SYSTEMIC DLBCL | Anna Kaisa Pasanen | Received |
247-P | RITUXIMAB IN COMBINATION WITH METHOTREXATE-BASED CHEMOTHERAPY WITH BLOOD-BRAIN BARRIER DISRUPTION IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA | Nancy Doolittle | Received |
249-P | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A RETROSPECTIVE ANALYSIS OF DATA FROM THE DANISH LYMPHOMA REGISTRY LYFO | Danny Stoltenberg | Received |
250-P | IELSG 34 FINAL RESULTS OF A MULTICENTER PHASE II STUDY TO EVALUATE THE CLINICAL ACTIVITY AND THE SAFETY OF EVEROLIMUS IN MARGINAL ZONE B-CELL LYMPHOMAS (MZL) | Annarita Conconi | Received |
253-P | RISK FACTORS AND STAGING SYSTEMS IN EARLY STAGE HODGKIN LYMPHOMA PATIENTS HAVE SIGNIFICANT IMPACT ON TREATMENT OUTCOME AFTER MODERN COMBINED MODALITY TREATMENT. | Beate Klimm | Received |
254-P | DEEP INSPIRATION BREATH HOLD RADIATION THERAPY REDUCES RADIATION DOSE TO HEART IN PATIENTS TREATED FOR MEDIASTINAL HODGKIN LYMPHOMA | Peter Meidahl Petersen | Received |
255-P | TAILORING THERAPY IN HODGKIN LYMPHOMA BASED ON PREDEFINED RISK FACTORS AND EARLY INTERIM PET/CT: ISRAELI H2 STUDY -PRELIMINARY REPORT ON 306 PATIENTS | Eldad J Dann | Received |
256-P | PATTERNS OF FAILURE (POF) IN A RANDOMIZED PHASE III TRIAL OF ABVD VS. STANFORD V /- RADIATION THERAPY (RT) IN LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKINS LYMPHOMA (HL): AN INTERGROUP STUDY COORDINATED BY THE EASTERN COOPERATIVE ONCOLOGY GROUP (E2496) | Henry Wagner | Received |
257-P | PHARMACOGENETIC ANALYSIS OF CYP2B6 IN THE LRF CLL4 TRIAL: THE 6 ALLELIC VARIANT IS ASSOCIATED WITH INFERIOR EFFICACY FOLLOWING FLUDARABINE PLUS CYCLOPHOSPHAMIDE | Gillian Johnson | Received |
258-P | THE PROGNOSTIC IMPACT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA REQUIRING FIRST-LINE THERAPY | Julio Delgado | Received |
259-P | A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. FINAL RESULTS OF DATABASE OF CLL OF SPANISH GROUP OF CYTOGENETICS AND SPANISH GROUP OF CLL | JOSE-ANGEL HERNANDEZ | Received |
260-P | FLUDARABINE, RITUXIMAB, AND LENALIDOMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Ian Flinn | Received |
261-P | PLATINUM AND HIGH-DOSE CYTARABINE-BASED REGIMENS ARE EFFICIENT IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA : RESULTS OF A RETROSPECTIVE MULTICENTER STUDY | Eric DUROT | Received |
262-P | CYTOKINE QUANTIFICATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB AND RITUXIMAB | Iris de Weerdt | Received |
264-P | THE EFFECT OF MOLECULAR SUBCLASS ON PATIENT OUTCOMES AFTER RADIOIMMUNOTHERAPY-BASED CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | Tanya Siddiqi | Received |
265-P | TREATMENT OF PERIPHERAL T-CELL LYMPHOMA WITH AGGRESSIVE INDUCTION CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT USING DENILEUKIN DIFTITOX (DD) FOR IN VIVO PURGING AND POST-TRANSPLANT THERAPY: PRELIMINARY RESULTS OF A PHASE II CLINICAL TRIAL | Lawrence Kaplan | Received |
266-P | AUTOLOGOUS AND ALLOGENEIC STEM-CELL TRANSPLANTATION FOR TRANSFORMED NON-FOLLICULAR INDOLENT LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP | Diego Villa | Received |
270-P | BASELINE METABOLIC TUMOR VOLUME PREDICTS PATIENTS OUTCOME IN HODGKIN LYMPHOMA | cédric rossi | Received |
271-P | FDG PET-CT AFTER FIRST-LINE TREATMENT PREDICTS PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) | Eukene Gainza | Received |
272-P | PROGNOSTIC VALUE OF 18FDG BASELINE FUNCTIONAL PET PARAMETERS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMLBCL) | Luca Ceriani | Received |
273-P | 18F-FLUORODEOXYGLUCOSE (FDG) OUTPERFORMS 18F-FLUOROTHYMIDINE (FLT) IN IDENTIFYING TRANSFORMATION OF FOLLICULAR LYMPHOMA, IN PARTICULAR THROUGH HETEROGENEITY IN UPTAKE | Marielle Wondergem | Received |
274-P | INTERIM PET SUVMAX REDUCTION IS SUPERIOR TO VISUAL ANALYSIS TO PREDICT PATIENTS OUTCOME IN HODGKIN LYMPHOMA | Cédric rossi | Received |
276-P | COMPARATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT (BMI) BY BM BIOPSY (BMB) OR POSITRON EMISSION TOMOGRAPHY (PET) IN HODGKIN LYMPHOMA (HL) | Theodoros Vassilakopoulos | Received |
277-P | A NOVEL ORAL BRUTONS TYROSINE KINASE (BTK) INHIBITOR THAT DEMONSTRATES POTENT PHARMACODYNAMIC ACTIVITY THROUGH PHOSPHORYLATED BTK (P-BTK) INHIBITION, IN ADDITION TO EFFECTIVE ANTI-TUMOUR ACTIVITY IN A DLBCL XENOGRAFT MODEL) | Toshio Yoshizawa | Received |
278-P | GENOMIC INSTABILITY AND ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS AND A PROMISING TARGET FOR THERAPY IN DIFFUSE LARGE B CELL LYMPHOMA | Enrico Derenzini | Received |
279-P | TARGETING SIGNALING PATHWAYS IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME | Wei Ai | Received |
281-P | A NEW THERAPEUTIC APPROACH FOR THE THERAPY OF B-CELL DISORDERS: DRUG-LOADED ANTI-CD20 NANOPARTICLES) | Gabriele Pozzato | Received |
284-P | DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NONHODGKIN LYMPHOMA | Patricia Pérez-Galán | Received |
285-P | EFFECTS OF RITUXIMAB AND GA-101 ON IN VITRO KILLING OF CELL LINES AND PATIENT LYMPHOMA CELLS BY NORMAL DONOR OR PATIENT EFFECTOR CELLS | Huei Shan Wu | Received |
289-P | BENDAMUSTINE, LENALIDOMIDE, AND RITUXIMAB IN RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES | Bruce Cheson | Received |
292-P | EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB (IR) IN HIGH-RISK CLL PATIENTS | Jan A. Burger | Received |
299-P | PHASE II MULTICENTER STUDY OF LENALIDOMIDE IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST-BORTEZOMIB: MCL-001 EMERGE STUDY | marybeth McKenzie | Received |
306-P | ARE MONOCLONAL ANTIBODIES NECESSARY IN THE TREATMENT OF CHILDRENS B-NON HODGKIN LYMPHOMA? | Josip Konja | Received |
308-P | OUTCOME AND TOXICITY PATTERNS IN CHILDREN WITH NON-HODGKINS LYMPHOMA | Oussama Abla | Received |
309-P | MANAGEMENT OF PEDIATRIC HODGKIN LYMPHOMA IN CROATIA | Josip Konja | Received |
310-P | RAPID EARLY RESPONSE TO HIGH-DOSE METHOTREXATE IN AN ADOLESCENT WITH MULTIFOCAL PRIMARY CNS LYMPHOMA | Oussama Abla | Received |
CLICK HERE TO SEE A PRESENTATION OF THE NEW-LOOK POSTERSESSIONONLINE VIEWER.
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|